VERTEX PHARMACEUTICALS INC / MA Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeNet · last filed 2013-03-01
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2012-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-12-31 was -$838.00K.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-09-30 was -$7.03M.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2011-06-30 was -$2.24M.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2012 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2011 was -$17.20M.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2010 was -$39.59M.
- VERTEX PHARMACEUTICALS INC / MA derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2009 was -$2.05M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 3 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 6 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 9 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 12 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-01 | |||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | -$838.00K derived: sum of 2 quarters · filed 2013-03-01 | -$7.87M derived: sum of 3 quarters · filed 2013-03-01 | -$10.11M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-12-31 | -$838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$7.87M derived: sum of 2 quarters · filed 2013-03-01 | -$10.11M derived: sum of 3 quarters · filed 2013-03-01 | -$17.20M 10-K · filed 2013-03-01 | ||||
| 2011-09-30 | -$7.03M 10-Q · filed 2012-11-06 | -$9.27M derived: sum of 2 quarters · filed 2012-11-06 | -$16.36M 10-Q · filed 2012-11-06 | -$22.04M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | -$2.24M 10-Q · filed 2012-08-08 | -$9.33M 10-Q · filed 2012-08-08 | -$15.01M derived: sum of 3 quarters · filed 2013-03-01 | -$24.05M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | -$7.09M 10-Q · filed 2012-05-10 | -$12.77M derived: sum of 2 quarters · filed 2013-03-01 | -$21.81M derived: sum of 3 quarters · filed 2013-03-01 | -$45.52M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | -$5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$14.72M derived: sum of 2 quarters · filed 2013-03-01 | -$38.42M derived: sum of 3 quarters · filed 2013-03-01 | -$39.59M 10-K · filed 2013-03-01 | $39.59M 10-K · filed 2011-02-17 | |||
| 2010-09-30 | -$9.04M 10-Q · filed 2011-11-03 | $9.04M 10-Q · filed 2010-10-28 | -$32.75M derived: sum of 2 quarters · filed 2011-11-03 | -$33.92M 10-Q · filed 2011-11-03 | $33.92M 10-Q · filed 2010-10-28 | |||
| 2010-06-30 | -$23.71M 10-Q · filed 2011-08-09 | $23.71M 10-Q · filed 2010-08-03 | -$24.88M 10-Q · filed 2011-08-09 | $24.88M 10-Q · filed 2010-08-03 | ||||
| 2010-03-31 | -$1.17M 10-Q · filed 2011-05-06 | |||||||
| 2009-12-31 | -$2.05M 10-K · filed 2012-02-22 | $2.05M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |